AI biomarker derived from routine data prognostic for patients with pancreatic cancer

Approximately a third of patients with pancreatic ductal adenocarcinoma do not have elevated or detectable levels of a biomarker commonly used to measure response to therapy.An AI tumor marker derived from routinely collected data could provide prognostic information on treatment completion and survival similar to that seen in patients who have measurable cancer antigen 19-9 (CA19-9).